The central role of these cytokines explains their therapeutic targeting in RA (TNF blockers: etanercept, adalimimab, infliximab, certolizumab, golimumab; IL6 blocker: tocilizumab; IL1 blocker: anakinra). Here, IL6 is linked to rheumatoid arthritis.